| DGX |
Report |
Q2 2026 adjusted EPS |
BEAT |
pred ~$2.86 vs. cons $2.81 |
MEDIUM |
| DGX |
Report |
Q2 2026 revenue |
BEAT |
pred ~$3.01B vs. cons $2.97B |
MEDIUM |
| DGX |
Report |
Q2 2026 adjusted operating margin |
IN-LINE |
pred ~16.7% vs. cons 16.6% |
LOW |
| DGX |
Guide |
FY2026 revenue guidance midpoint |
BETTER |
guide ~$11.92B vs. cons $11.88B (FY2026) |
MEDIUM |
| DGX |
Guide |
FY2026 adjusted EPS guidance midpoint |
BETTER |
guide ~$10.88 vs. cons $10.72 (FY2026) |
MEDIUM |
| DGX |
Guide |
FY2026 operating cash flow guidance |
UNCHANGED |
guide ~$1.75B vs. cons $1.75B (FY2026) |
HIGH |
| DGX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.8% |
— |
MEDIUM |
| DGX |
Return |
5-day cumulative residual |
+3.8% (FOLLOW-THROUGH) |
Predicted FY2026 adjusted EPS guide of ~$10.88 vs. consensus $10.72 implies second-half adjusted EPS of ~$5.52 versus the pre-report consensus implied ~$5.41, supporting modest upward revisions after the initial beat despite the elevated valuation. |
LOW |